Obesity is one of the world’s leading public health problems. The proportion of individuals falling into the severely overweight–obese category is increasing at an alarming rate, especially in children. Coincident with increased adiposity is the risk for developing glucose intolerance, the so-called metabolic syndrome, and type 2 diabetes. Charles River Discovery Research Services offers services for the assessment of therapeutic agents designed to interfere with diet induced obesity (DIO). Our offerings provide a flexible platform for the assessment of physiologic changes and the attendant biomarkers associated with DIO. Combining your choice of species, strain, diet and analytical parameters, we can customize studies to suit the individual needs of our clients.
For more information about our diet-induced obesity and dyslipidemia models, please contact us at 1.877.CRIVER.1 or email@example.com.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.
We offer a package of well-established, state of the art in vitro mode of action assays that are suitable for early phase biocomparability studies, lot release and stability. These tests can accelerate the time it takes to get a new product ready for market submission.
May 20–May 22
Please visit Charles River tabletop #611 to discuss our full portfolio of products and services, including our Preclinical Services, as well as our Biopharmaceutical Services, which deliver client-focused solutions for the specific testing and manufacturing requirements of your biologic.
May 23–May 23
This full-day seminar encompasses selected topics from our Charles River Short Course on Laboratory Animal Science. We would like to acknowledge Michigan State University for hosting this event and extend our heartfelt thanks to guest speaker Dr. Danielle Ferguson.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.